Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
  •  The A Shares of the Company will be listed and commence trading on the STAR Market of the Shanghai Stock Exchange on 19 June 2020 2020-06-18
  • The Company determined the offer size and offer price for the Issue of A Shares 2020-06-09
  • The Company determined the issue price range of the Issue of A Shares 2020-06-05
  • The Company determined the online roadshow time of the Issue of A Shares 2020-06-04
  • The Company will conduct a preliminary price consultation of the Issue of A Shares on the preliminary price consultation day (i.e. 3 June 2020) 2020-05-29 09:10
  • The China Securities Regulatory Commission has approved the Company’s application for the registration of the Issue of A Shares on 14 May 2020. 2020-05-14 18:10
  • Application for the Proposed Issue of A Shares has been approved by the Listing Committee for Sci-tech Innovation Board of Shanghai Stock Exchange on 3 April 2020. 2020-04-03 17:48
  • The subsidiary of FDZJ was awarded the Top Ten Innovative Industrial Enterprises 2019-07-17 10:44
  • Application for the Sci-Tech Innovation Board has been accepted 2019-05-13 19:20
  • FDZJ has transferred rights of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection, which was independently developed by FDZJ, to a third-party 2019-03-14 16:20
  • FDZJ was awarded “Outstanding Contribution to Economy” by Shanghai Pudong New Area People’s Government 2018-4-30 15:50
  • As a subsidiary of FDZJ, Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd. was identified as “Hi-Tech Enterprise” by Jiangsu Government 2018-12-10 17:10
  • As Category 1 of Therapeutic Biological Product, “Recombinant Anti-CD30 Human-mouse Chimeric Monoclonal” has achieved Clinical Trial Permission with approval number of 2018L02789 2018-07-20 10:30
  • In 2017, two projects were funded by Shanghai Science & Technology Commission, one project received funding from China's Ministry of Science and Technology. 2017-12-30 16:50
  • FDZJ successfully achieved IPMS certification. 2017-10-18 15:06
  • The Permission for Clinical Trial for Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection was issued 2017-02-01 10:35
  • The official market launch of FuMeiDa from FDZJ brought new hope to patients with port wine stains 2016-12-05 14:20
  • The success of obtaining drug approval of Hemoporfin (FuMeiDa) as a class 1 new drug 2016-10-20 14:00
  • Air conditioning system design of small capacity injection workshop won the award of CIFA-ISPE 2016-04-19 10:10
  • ALA® has been successfully selected the "National New Products Program" and awarded as the "National Strategic Innovative Product" 2015-04-03 12:50
  • Page: 1/3  Per Page20  Total 45  No.: [1][2][3]

    Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
    (沪)-非经营性-2019-0143    沪ICP备10027510号-1